[1]叶赛,鲁一兵.肠道激素多受体激动剂治疗代谢性疾病的研究进展[J].国际内分泌代谢杂志,2022,42(06):477-480.[doi:10.3760/cma.j.cn121383-20211009-10013]
　Ye Sai,Lu Yibing..Progress of intestinal hormone multi-receptor agonists in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2022,42(06):477-480.[doi:10.3760/cma.j.cn121383-20211009-10013]
点击复制

肠道激素多受体激动剂治疗代谢性疾病的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年06期
页码:
477-480
栏目:
综述
出版日期:
2022-11-20

文章信息/Info

Title:
Progress of intestinal hormone multi-receptor agonists in the treatment of metabolic diseases
作者:
叶赛; 鲁一兵
南京医科大学第二附属医院内分泌科 210011
Author(s):
Ye Sai;  Lu Yibing.
Department of Endocrinology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China
关键词:
肠道激素;  胰高血糖素样肽-1受体激动剂;  2型糖尿病;  多受体激动剂;  代谢性疾病
Keywords:
Intestinal hormone;  Glucagon-like polypeptide-1 receptor agonist;  Type 2 diabetes mellitus;  Multi receptor agonists;  Metabolic diseases
DOI:
10.3760/cma.j.cn121383-20211009-10013
摘要:
肠道内产生多种肠道激素,其中胰高血糖素样肽-1(GLP-1)受体激动剂具有降糖、减重、心血管保护等作用。以GLP-1为主、融合其他肠道激素的多受体激动剂在促进胰岛素分泌、增加机体产热和肝脏脂肪分解、抑制食欲等作用上相互加强,提高了降低血糖、减轻体重、改善脂肪代谢等方面的临床疗效。除了治疗2型糖尿病(T2DM)以外,肠道激素多受体激动剂还有望用于治疗肥胖症、非酒精性脂肪性肝炎(NASH)等代谢性疾病。
Abstract:
A variety of gut hormones are produced in the intestine, among which glucagon-like peptide-1 receptor agonists have glucose-lowering, weight-loss, and cardiovascular protective effects. Glucagon-like polypeptide-1-based multiple agonists fused with other intestinal hormones reinforce each other in promoting insulin secretion, increasing body thermogenesis and hepatic lipolysis, and suppressing appetite, improving clinical efficacy in lowering blood glucose, reducing body weight, and improving fat metabolism. In addition to the treatment of type 2 diabetes mellitus, intestinal hormone multiple agonists are expected to be used for the treatment of metabolic diseases such as obesity and nonalcoholic steatohepatitis.

参考文献/References:

[1] Müller TD,Finan B,Bloom SR,et al.Glucagon-like peptide 1(GLP-1)[J].Mol Metab,2019,30:72-130.DOI:10.1016/j.molmet.2019.09.010.
[2] El K,Campbell JE.The role of GIP in α-cells and glucagon secretion[J].Peptides,2020,125:170213.DOI:10.1016/j.peptides.2019.170213.
[3] Bailey CJ.GIP analogues and the treatment of obesity-diabetes[J].Peptides,2020,125:170202.DOI:10.1016/j.peptides.2019.170202.
[4] Min T,Bain SC.The Role of Tirzepatide,Dual GIP and GLP-1 receptor agonist,in the management of type 2 diabetes:the SURPASS clinical trials[J].Diabetes Ther,2021,12(1):143-157.DOI:10.1007/s13300-020-00981-0.
[5] Ludvik B,Giorgino F,Jódar E,et al.Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes(SURPASS-3):a randomised,open-label,parallel-group,phase 3 trial[J].Lancet,2021,398(10300):583-598.DOI:10.1016/S0140-6736(21)01443-4.
[6] Urva S,Quinlan T,Landry J,et al.Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide[J].Clin Pharmacokinet,2021,60(8):1049-1059.DOI:10.1007/s40262-021-01012-2.
[7] Janah L,Kjeldsen S,Galsgaard KD,et al.Glucagon receptor signaling and glucagon resistance[J].Int J Mol Sci,2019,20(13):3314.DOI:10.3390/ijms20133314.
[8] Kosinski JR,Hubert J,Carrington PE,et al.The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin[J].Obesity(Silver Spring),2012,20(8):1566-1571.DOI:10.1038/oby.2012.67.
[9] Ambery P,Parker VE,Stumvoll M,et al.MEDI0382,a GLP-1 and glucagon receptor dual agonist,in obese or overweight patients with type 2 diabetes:a randomised,controlled,double-blind,ascending dose and phase 2a study[J].Lancet,2018,391(10140):2607-2618.DOI:10.1016/S0140-6736(18)30726-8.
[10] Nahra R,Wang T,Gadde KM,et al.Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes:a 54-week randomized phase 2b study[J].Diabetes Care,2021,44(6):1433-1442.DOI:10.2337/dc20-2151.
[11] Schiavon M,Visentin R,Göbel B,et al.Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide[J].Diabetes Obes Metab,2021,23(8):1795-1805.DOI:10.1111/dom.14394.
[12] Pathak V,Flatt PR,Irwin N.Cholecystokinin(CCK)and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes[J].Peptides,2018,100:229-235.DOI:10.1016/j.peptides.2017.09.007.
[13] Hornigold DC,Roth E,Howard V,et al.A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice[J].Appetite,2018,127:334-340.DOI:10.1016/j.appet.2018.05.131.
[14] Gault VA,Bhat VK,Irwin N,et al.A novel glucagon-like peptide-1(GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide,GLP-1,and glucagon receptors and therapeutic potential in high fat-fed mice[J].J Biol Chem,2013,288(49):35581-35591.DOI:10.1074/jbc.M113.512046.
[15] Cui J,Shang A,Wang W,et al.Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia,obesity and diabetic nephropathy in rodent animals[J].Life Sci,2020,260:118339.DOI:10.1016/j.lfs.2020.118339.
[16] Willard FS,Douros JD,Gabe MB,et al.Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist[J].JCI Insight,2020,5(17):e140532.DOI:10.1172/jci.insight.140532.
[17] Henderson SJ,Konkar A,Hornigold DC,et al.Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates[J].Diabetes Obes Metab,2016,18(12):1176-1190.DOI:10.1111/dom.12735.
[18] Hartman ML,Sanyal AJ,Loomba R,et al.Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes[J].Diabetes Care,2020,43(6):1352-1355.DOI:10.2337/dc19-1892.
[19] Kannt A,Madsen AN,Kammermeier C,et al.Incretin combination therapy for the treatment of non-alcoholic steatohepatitis[J].Diabetes Obes Metab,2020,22(8):1328-1338.DOI:10.1111/dom.14035.
[20] Gupta NA,Mells J,Dunham RM,et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway[J].Hepatology,2010,51(5):1584-1592.DOI:10.1002/hep.23569.
[21] Hölscher C.Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models[J].Neuropharmacology,2018,136(Pt B):251-259.DOI:10.1016/j.neuropharm.2018.01.040.
[22] 焦娟娟,Christian Hölscher,李甜,等.GLP-1/GIP/Gcg三受体激动剂改善阿尔茨海默病三转基因小鼠的认知行为[J].生理学报,2017,69(2):135-145.DOI:10.13294/j.aps.2017.0005.
[23] Wilson JM,Nikooienejad A,Robins DA,et al.The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist,tirzepatide,improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes[J].Diabetes Obes Metab,2020,22(12):2451-2459.DOI:10.1111/dom.14174.
[24] Harada T,Obokata M.Obesity-related heart failure with preserved ejection fraction:pathophysiology,diagnosis,and potential therapies[J].Heart Fail Clin,2020,16(3):357-368.DOI:10.1016/j.hfc.2020.02.004.

相似文献/References:

[1]周欢欢,徐书杭,刘超,等.肠促胰素类降糖药物对体重的作用[J].国际内分泌代谢杂志,2016,36(03):172.[doi:10.3760/cma.j.issn.1673-4157.2016.03.07]
　Zhou Huanhuan*,Xu Shuhang,Liu Chao,et al.Effects of incretin drugs on body weight[J].International Journal of Endocrinology and Metabolism,2016,36(06):172.[doi:10.3760/cma.j.issn.1673-4157.2016.03.07]
[2]乔冠华,李强.胰高血糖素样肽-1受体激动剂治疗多囊卵巢综合征的研究进展[J].国际内分泌代谢杂志,2017,37(03):181.[doi:10.3760/cma.j.issn.1673-4157.2017.03.010]
　Qiao Guanhua,Li Qiang..Glucagon like peptide-1 receptor agonist in the treatment of polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2017,37(06):181.[doi:10.3760/cma.j.issn.1673-4157.2017.03.010]

备注/Memo

备注/Memo:
通信作者:鲁一兵,Email:luyibing2004@126.com
更新日期/Last Update: 2022-12-01